884408 - 500 Beiträge pro Seite

[User5]

hallo an alle,

habe den englischen text mit translator übersetzen lassen...

Donnerstag September 21, 7:05 sind Ost Time
Presse-Freilassung
Britischer Biotech plc Chairman`s Statement bei Jährlicher Allgemeiner Versammlung
OXFORD, England-- (UNTERNEHMEN-WIRE)--Sept. 21, 2000-- Der Vorsitzende von britischem Biotech, Mr Christopher Hampson, machte die folgende Behauptung bei der Jährlichen Allgemeinen Versammlung von Aktionären der Gesellschaft heute:

Weil ich mit Ihnen beim letzten AGM sprach, hat sich Ihre Gesellschaft auf das Ausführen der Strategie konzentriert, ich umriß letztes Jahr. Ich glaube, daß beträchtlicher Fortschritt gemacht worden ist, und, als ein Ergebnis ist eine starke Plattform, auf der Ihre Gesellschaft fortsetzen kann, zu bauen, geschaffen worden. Die Strategie ist zu:

beuten Sie unsere Eigentums metalloenzyme-Hemmung-Programme aus;
entdecken Sie und entwickeln Sie neue Klassen von Antibiotikas;
entwickeln Sie Spezialist-Drogen für die Behandlung von Krebs und Aufflammen; und
operieren Sie in sowohl USA als auch Europa
Diese Strategie wird zur Entwicklung einer Produkt-Aktentasche mit innovatorischen neuen Gelegenheiten führen, in Krebs, Infektion und Aufflammen beide von innererer Forschung und externen Quellen. Ausdehnung der Aktentasche ist ein Schlüssel-Element der Company`s Strategie und ist wesentlich, genügende Droge-Entwicklung-Gelegenheiten zu, die Produkt-Mißerfolge zu berücksichtigen, die in unserem Unternehmen unvermeidlich sind, produzieren. Wir werden fortsetzen, neue Produkte zu unserer Aktentasche durch Zusammenarbeit mit dritten Parteien hinzuzufügen und durch unsere eigenen Forschung-Aktivitäten.

Vor einem Jahr hatte die Gesellschaft drei Produkte in Entwicklung. Im Verlauf den vergangenen 12 Monaten haben wir die Aktentasche verdoppelt, die ich kurz jetzt beschreiben werde.

Das Drehen zu den ersten drei Produkten. In September 1999 schafften wir eine Zusammenarbeit mit Schering-Pflug, zu entwickeln und Matrize-metalloproteinase-Schutzmittel für Krebs zu kommerzialisieren, einschließlich marimastat. Dies versorgte das gesamte Programm mit beidem Indossament und trug zum Finanzieren für das Unternehmen bei. Wir haben Ergebnisse jetzt von vier klinischen Studien mit marimastat gehabt und, während jedes Studium seinen primären Ende-Punkt gescheitert ist, hat es irgendeinen Beweis klinischer Aktivität beide in Patienten mit gastrischem Krebs gegeben und in Patienten mit weniger umfangreicher Krankheit. Ergebnisse von zwei Phase III Studien in kleinem Zell Lunge-Krebs werden später dieses Jahr erwartet oder früh in 2001 und ist wahrscheinlich, die Zukunft für marimastat zu bestimmen. Inzwischen, eine Phase ich Maximum tolerierte Dosis-Studium mit BB-3644, eine Sekunde-Generation MMPI für die Behandlung von Krebs, begann in November 1999. Herstellung von BB-10153, eine Klumpen-auflösende Droge, ist outsourced gewesen, während die Gesellschaft einen Partner sucht, zu entwickeln und diesen Agenten zu kommerzialisieren.

Drei neue Verbindungen sind zu unserer Entwicklung-Aktentasche hinzugefügt worden. Zwei entstanden von britischem Biotech`s eigene Forschung-Aktivitäten und überstiegen letzten year`s objektiv von einer Verbindung. Diese Verbindungen sind BB-2827, ein collagenase-Schutzmittel für Gelenkrheumatismus, und BB-76163, ein aminopeptidase-Schutzmittel für ernste aufrührerische Krankheit. Das dritte neue Produkt ist huN901-DM1, ein gezielt auf cytotoxic für die Behandlung kleinen Zell Lunge-Krebses, die von ImmunoGen Inc. entdeckt wird, den eine Gesellschaft in Boston gründete. Dies ist das erste Produkt, das von britischem Biotech in-genehmigt werden sollte. Wir werden es gemeinsam in Zusammenarbeit mit ImmunoGen entwickeln und, in Rückkehr, hat die Rechte bekommen, das Produkt in Europa und Japan zu kommerzialisieren.

Die Gesellschaft beabsichtigt, Wert hauptsächlich von seinen Produkten durch das Bilden von Entwicklung und das Verkaufen von Zusammenarbeiten mit pharmazeutischen oder anderen Biotechnik-Gesellschaften zu erkennen. Britischer Biotech wird Kommerzialisierung-Rechte aber für die Behandlung von Nische-Märkten behalten.

Im letzten Viertel verringerte die Gesellschaft und reorganisierte, um Ressourcen auf Droge-Entwicklung zu konzentrieren, während das Beibehalten einer Kern-Forschung-Fähigkeit, die auf metalloenzymes abzielt. Unsere Forschung wird jetzt auf neuen Klassen von Antibiotikas konzentriert, mußte die Probleme bakteriellen Widerstandes überwältigen. Das Blei-Programm zielt auf einen bakteriellen metalloenzyme, polypeptide-deformylase, ab und wird erwartet, um eine Verbindung für Entwicklung durch das Ende des Jahres zu produzieren. Mir wird gefallen, um zu sagen, daß unsere Gesellschaft das erste veröffentlicht Patent in diesem Feld hat. Um die chemische Vielfalt unseres Anti-bakteriellen Programms zu vergrößern, haben wir vor kurzem in eine Zusammenarbeit mit De Novo Arzneimitteln, eine Cambridge-basierte Gesellschaft, die sich auf molekulares Design spezialisiert, betreten.

Als ein kritischer Teil der Umorganisation sind der Company`s Research und die Entwicklung integriert worden. Wir haben eine starke Entwicklung-Fähigkeit mit den Sachverstand geschafft, um Produkt-Entwicklung in Nordamerika und Europa zu unternehmen. Wir glauben, als von der Zusammenarbeit mit ImmunoGen erläutert, daß diese Fähigkeit uns zu einem attraktiven Partner für viele biotech und kleine pharmazeutische Gesellschaften macht, insbesondere in der USA.

Externe Besprechung ist zur Bedienung unseres Unternehmens wesentlich. Ein Wissenschaftliches Beratendes Brett, das von internationalen Experten wieder vertragen wird, wird auf der Company`s Forschung und den Entwicklung-Programmen konsultiert. Außerdem sind Zusammenarbeiten mit Außen Gesellschaften wie CareScience und Agilent geschafft worden, um Schlüssel-Schritte in Droge-Entwicklung zu verbessern. Weiterhin hat die Gesellschaft eine unabhängige Sicherheit Beratendes Brett ernannt, klinische Versuche zu überprüfen.

In Respekt finanziellen Managements ist der bar Brandfleck zu reduziert worden (pound)22 Million, verglich mit (pound)34.5 Million im vorausgehenden Jahr, das Resultieren in Bargeld-Gleichgewichten von (pound)75 Million beim 30. April. Management-Handlung headcount zu reorganisieren und zu reduzieren hat die reparieren-Preis-Basis des Unternehmens heruntergelassen. Die Gesellschaft wird gut gesetzt, um in seiner Aktentasche im Verlauf der nächsten drei Jahre zu investieren.

In Schluß hat das vergangene Jahr herausgefordert, aber hat die Gesellschaft eine starke Plattform für die Zukunft schaffen gesehen. Die Aktentasche hat jetzt in Größe mit sechs Produkten in Entwicklung verdoppelt. Wir haben eine klare Strategie, neue Gelegenheiten zu, Wert für Aktionäre zu bauen schaffen und zu verfolgen.

Britischer Biotech

Britischer Biotech ist ein öffentlich getauschter Entwicklung-Abschnitt pharmazeutische Gesellschaft (LSE: BBG, NASDAQ,: BBIOY) welcher baut eine Aktentasche von Produkten für die Behandlung von Krebs, Aufflammen und ansteckender Krankheit. Diese Gelegenheiten werden von betriebsinterner Forschung und Entwicklung erzeugt werden und durch Erwerb von, und Zusammenarbeit mit, außerhalb Parteien.

Britischer Biotech hat gegenwärtig sechs Produkte in Entwicklung. Marimastat, ein Matrize-metalloproteinase-Schutzmittel, ist in Phase III Entwicklung für die Behandlung von Krebs, BB-3644, ein folgen-auf zu marimastat, ist in Phase ich Entwicklung für Krebs, und BB-10153 hat Phase vervollständigt ich Entwicklung für kardiovaskuläre Krankheit. BB-2827, ein collagenase-Schutzmittel für Aufflammen, huN901-DM1, ein gezielt auf cytotoxic für kleinen Zell Lunge-Krebs, und BB-76163, ein aminopeptidase-Schutzmittel für ständige aufrührerische Krankheit, sind in preclinical-Entwicklung.

Diese Nachricht-Freilassung enthält zukunftsweisende Behauptungen, die den Company`s aktuelle Erwartung hinsichtlich künftiger Ereignisse widerspiegeln. Zukunftsweisende Behauptungen bringen Risikos und Ungewißheiten mit sich. Eigentliche Ereignisse könnten sich wesentlich von unterscheiden jenes vorhergesagt hierin und hängt von einer Anzahl von Faktoren einschließlich des Erfolges der Company`s Forschung Strategie ab, die Anwendbarkeit der Entdeckungen machte therein, die erfolgreiche und rechtzeitige Vervollständigung von klinischen Studien und den Ungewißheiten erzählte zum vorschriftsmäßigen Prozeß.


hoffen wir auf baldigen kursanstieg

gruss
user5

[User5]

Embargoed until 11.15am, 23rd September 1999
British Biotech plc
Chairman`s statement at Annual General Meeting

The Chairman of British Biotech, Mr Christopher Hampson, made the following
statement at the Annual General Meeting of shareholders of the Company today:

"This is my first Annual General Meeting as Chairman of your Company. Looking back it
has been a year of many challenges and a difficult period for your Company, its
shareholders and staff. I am pleased that, recently, the Company has been able to report
some success and I look forward to building on the recent achievements as our strategy is
put into effect.

The key points of the strategy are:

* to focus on innovative discovery research, principally on metalloenzyme inhibition,
and to take one new compound, on average, into development each year;

* to broaden the product portfolio through adding compounds which have been
discovered elsewhere;

* to focus the development capability on taking compounds through the early stages of
clinical development to establish `proof of principle`; and

* to seek partnerships with experienced pharmaceutical groups to complete the
development of any compounds and then to market them worldwide.

This strategy is now being implemented as evidenced by the recent collaboration with
Schering-Plough in respect of our matrix metalloproteinase inhibitor, or MMPI,
programme in cancer. We believe that Schering-Plough will be an excellent partner for
British Biotech. They are one of the leading pharmaceutical companies in the world with
significant experience in the development and marketing of oncology products. They
meet all the criteria that British Biotech established when we decided to seek an
international partner to develop and market MMPIs in cancer. In addition to securing a
strong partner to develop and commercialise our products, the collaboration brings other
benefits to your Company.

First, Schering-Plough have undertaken extensive due diligence on both the MMPI
programme and the business generally and the collaboration is a strong endorsement of
both. Second, our commitment to MMPIs in cancer is now clearly defined in both
operational and financial terms which enables the Company to increase the strategic
flexibility of the business by broadening its portfolio both from opportunities within the
business and discovered elsewhere. Lastly, the milestone income supports our important
target of reducing the cash-burn and thus improving the sustainability of the Company.

Another consequence of the revised strategy has been the ability to concentrate our
people and financial resource on core areas of research and development. This focus has
enabled us to reduce expenditure levels materially and thus extend the life of our existing
cash balances. You should expect further reductions this year as the new strategy is
implemented and the streamlined operating structure takes full effect. Extending the life
of the Company`s cash balances is a major objective for all managers within the Company
as we seek to build a sustainable and profitable business.

There have been mixed results from our clinical trial programmes during the year. The
development of Zacutex as a treatment for acute pancreatitis was discontinued following
the results from Study 215, which failed to show positive results from the drug. Results
from two of the 10 pivotal studies which are under way with marimastat have been
reported. Both Study 128, in patients with advanced pancreatic cancer, and Study 145,
in patients with advanced gastric cancer, failed to meet their primary end points.
However, both trials showed evidence of activity and Study 145, in particular, produced
some interesting data which showed that marimastat may be demonstrating a survival
benefit in patients with gastric cancer, especially in longer-term follow up of patients.
We are working closely with our partner, Schering-Plough, and intend to consult with
regulatory authorities to determine how best to proceed in gastric cancer.

BB-3644 is a second-generation MMPI which is under development as an anti-cancer
agent and has also been licensed to Schering-Plough. Pre-clinical models indicate that
BB-3644 is less prone to cause tendinitic side effects while preserving the anti-cancer
effect. On 14th September 1999, the Medicines Control Agency, the UK regulator, gave
the Company approval to commence a clinical trial in cancer patients with BB-3644.
This will commence shortly.

The Company`s research is focused on the inhibition of metalloenzymes which control a
broad range of biological processes. As a result, metalloenzyme inhibitors promise to be
of potential benefit in many clinical conditions such as cancer, inflammatory and
infectious diseases. One example of our progress within discovery research this year is in
the anti-bacterial metalloenzyme inhibition project which is focused on infectious
disease. Recently, a number of bacteria have been encountered which are resistant to all
known antibiotics and there is, therefore, a clear medical need for new antibiotics.

The Company has filed a number of patent applications covering a new class of potential
antibiotic drugs that are effective against these resistant bacteria and the first of these was
published in August. As far as we know this is the first such patent application to reach
the public domain which means that, although the project is at an early stage, the
Company is in a strong position in the search for a new class of antibiotic. Since the
Company has little experience in developing new antibiotics, the decision has been taken
to begin partnership discussions at this stage rather than later on. This is just one
example of our late-stage research programmes. In addition, we have four other late-
stage programmes focused on cancer, inflammatory and infectious diseases. Overall, our
target is to take one internally-generated research compound, on average, into
development annually.

In conclusion, therefore, the past year has been difficult for the Company but substantial
progress has been made. We have a strong management team and a clear strategy in place
upon which to build a sustainable business and deliver long-term shareholder value."

Ends

For further information, please contact:

British Biotech plc
Tony Weir, Finance Director 01865 781166

Ludgate Communications
David Simpson 0171 216 4567

[Frank012]

Embargoed until 17th October 2000, 6.00am


British Biotech plc ("British Biotech")
Serono & British Biotech to collaborate on inflammatory
diseases

Geneva, Switzerland, and Oxford, UK, 17th October, 2000 – Serono S.A. (SWX:
SEO and NYSE: SRA) and British Biotech plc (LSE: BBG and NASDAQ: BBIOY), today
announced that they have entered into an exclusive agreement to jointly research, develop
and commercialise metalloenzyme inhibitors (MEIs) for the treatment of serious
inflammatory diseases. In addition, British Biotech announces that BB-2827, a
collagenase inhibitor that is a potential treatment for rheumatoid arthritis, entered
clinical development in October 2000.

Serono and British Biotech will work together under the agreement to identify new
compounds for clinical development based on British Biotech`s proprietary MEI platform
technologies. Any compounds selected for clinical development will then be progressed
under the terms of an exclusive licence, development and commercialisation agreement.
Included within the scope of the agreement is an option for Serono to obtain exclusive
rights to develop and commercialise BB-2827 following completion of certain clinical
studies by British Biotech. Serono also gains rights to BB-76163, an aminopeptidase
inhibitor with potential application in multiple sclerosis.

“This partnership brings together Serono’s expertise in multiple sclerosis and other
inflammatory diseases with British Biotech’s leading position in metalloenzyme
inhibition,” commented Silvano Fumero, Senior Executive Vice President of Research &
Pharmaceutical Development at Serono. “We will continue to enhance our competitive
advantages in strategic research areas and to strengthen our early stage development
pipeline by partnering in the drug discovery process.”

Dr Elliot Goldstein, Chief Executive of British Biotech, said, “This is an important, long-
term research and development collaboration to bring new compounds to market with an
emerging world leader in inflammatory disease. The relationship with Serono continues
our strategy of collaboration with excellent partners to exploit our MEI platform,
develop new drugs in inflammatory disease and expand our portfolio of
commercialisation rights. In addition, we have met the important objective of starting
clinical trials with BB-2827.”

Under the terms of the agreement, British Biotech will receive from Serono an initial
payment of US$5 million, a series of undisclosed milestone payments, and eventual
royalties on any commercialised products. The companies will share the costs of research
equally. Costs of product development will be borne by Serono, but British Biotech has
the right to fund half of such costs and, in certain circumstances, may co-promote
products with Serono, for an improved return on sales. Depending on the achievement of
certain milestones, cash payments and research funding to British Biotech during the
term of the collaboration could total between US$30 million and US$80 million.

Ends


For more information, please contact:


British Biotech plc, Oxford, UK:
Tony Weir, Finance Director Tel: [phone]
Fax: [phone]
www.britishbiotech.com
Financial Dynamics, London, UK:
Sarah Mehanna/David Yates Tel: + 44 207 831 3113
Fax: + 44 207 242 8695
www.fd.com


Serono International S.A., Geneva,
Switzerland:
Media Relations:
Investor Relations:
Noonan/Russo
Communications:
Tel: [phone]
00
Tel: [phone]
Tel: [phone]
Fax: [phone]
85
Fax: [phone]
Fax: [phone]
Internet: www.serono.com
Reuters: SEOZ.S/SRA.N
www.noonanrusso.com

Bloomberg: SEO SW/SRA US
Tel: [phone]


Fax: [phone]





This news release contains forward-looking statements which reflect the Company`s current expectation
regarding future events. Forward-looking statements involve risks and uncertainties. Actual events
could differ materially from those projected herein and depend on a number of factors including the
success of the Company`s research strategy, the applicability of the discoveries made therein, the
successful and timely completion of clinical studies and the uncertainties related to the regulatory
process.


Notes to Editors

Serono

Serono, headquartered in Geneva, Switzerland, is a global biotechnology leader. The
Company has four recombinant products on the market: Gonal-F®, Rebif®, Serostim®
and Saizen®. In addition to being the world leader in reproductive health, Serono has
strong market positions in neurology, metabolism and growth. The Company`s research
programmes are focused on growing these businesses and on establishing new therapeutic
areas. Currently, there are seven products in development including six recombinant
proteins.

In 1999, Serono achieved worldwide sales of US$1.054 billion and a net income of
US$183.7 million, making it the third largest biotech company based on revenues. The
Company operates in 45 countries, and its products are sold in over 100 countries.
Bearer shares of Serono S.A., the holding company, are traded on the SWX Swiss
Exchange (SEO) and its American Depositary Shares are traded on the New York Stock
Exchange (SRA).


British Biotech

British Biotech is a research and development stage company (LSE: BBG, NASDAQ:
BBIOY). Its strategy is to build shareholder value by exploiting its proprietary
programmes in metalloenzyme inhibition; discovering and developing new classes of
antibiotics; developing specialist drugs for the treatment of cancer and inflammation; and
operating in both the USA and Europe.

The Company has six products in development and is actively expanding its portfolio
through its own research and collaboration with third parties. Value from products will
be realised via development and marketing collaborations with pharmaceutical and
biotech companies, and by retaining commercialisation rights to niche markets.

Four products are in clinical development. Marimastat, a matrix metalloproteinase
inhibitor, is in Phase III development for the treatment of cancer, BB-3644, a follow-on
to marimastat, is in Phase I development for cancer, BB-10153 has completed Phase I
development for cardiovascular disease; and BB-2827, a collagenase inhibitor for
inflammation, is in Phase I development. huN901-DM1, a targeted cytotoxic for small
cell lung cancer, and BB-76163, an aminopeptidase inhibitor for chronic inflammatory
disease, are in preclinical development.

British Biotech has developed a proprietary compound library, targeted at metalloenzyme
inhibition which lends itself to exploitation in a number of different therapeutic areas.
This metalloenzyme inhibitor platform is being exploited in-house in the area of bacterial
infections and by collaboration in other therapeutic areas.



Metalloenzymes

Metalloenzymes are characterised by one or more active site catalytic metal ions. They
have a wide range of specific biological activities including peptidase and non-peptidase
activity residing in the intra- and extra-cellular environments. They are implicated in a
wide range of diseases, including hypertension, cancer, bacterial infection and
inflammation.

Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic and often progressive debilitating disease of the
central nervous system that primarily affects young adults. It is an autoimmune disease in
which the body’s immune system reacts against its own cells, thereby destroying the
myelin sheath that protects the axons in the central nervous system. Damage to the
myelin sheath impedes the normal transmission of nervous impulses. These interruptions
of transmission cause motor and sensory difficulties. The progress of the disease is highly
variable. However, in its most severe forms, MS leads to rapidly progressive disability and
death.

Over one-half of the world’s estimated one million people with MS suffer from the
relapsing-remitting form of this disease, or RRMS, and nearly 80 per cent of all MS cases
start with RRMS. RRMS patients suffer from relapses or exacerbations, which are
unpredictable occurrences of new symptoms or worsening of old symptoms punctuated
by remissions.

Serono estimates that the treatment of MS was an approximately US$1.4 billion global
market in 1999, based on publicly reported sales data for its beta-interferon product,
Rebif® (US$143 million), and three competing products. Rebif is a recombinant
interferon beta-1a that helps strengthen the body’s immune system, and is identical to
the interferon beta produced by the body in response to viral infections. Rebif is offered
in two dosing regimens, 22 mcg three times per week, and 44 mcg three times per week,
as a unique liquid formulation in a pre-filled syringe. The 44 mcg dose is the highest
dose of interferon beta-1a currently approved for RRMS. Rebif is the fastest-growing
treatment for MS outside of the US with a patient market share of approximately 28 per
cent at 30th June 2000.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects various parts of
the body and is one of the most common forms of arthritis. It is characterised by the
inflammation of the membrane lining the joint, which causes pain, stiffness, warmth,
redness and swelling. The inflamed joint lining, the synovium, can invade and damage
bone and cartilage. Inflammatory cells release enzymes that may digest bone and
cartilage. The involved joint can lose its shape and alignment, resulting in pain and loss of
movement. RA is often chronic, and can be a disease of flares (active) and remissions
(little to no activity). Current treatment of rheumatoid arthritis focuses on reducing
swelling, relieving pain and stiffness, reducing inflammation and maintaining normal joint
function.

Worldwide, RA affects between 1-2 per cent of the total adult population. Its incidence
ranges from 0.3 to 1.5 per cent in most populations of the world, with women being
three times more likely to get rheumatoid arthritis than men. Western countries generally
see between 1-3 per cent of their populations affected.

Serono is active in the area of rheumatoid arthritis, and is conducting two Phase II trials
in this disease area, looking at recombinant human interferon beta-1a and recombinant
human tumor necrosis factor-binding protein (r-hTBP-1) as potential treatments.

Page 1 of 1

[User5]

hallo an alle,

heute steht der kurs schon auf 0,46 in frankfurt...weiter so nach norden.
wird zeit das die aktie nach norden geht.
user5

[User5]

Hallo,

Embargoed until 7.00am 19 th January 2001
British Biotech plc ("British Biotech")
Board changes
British Biotech is pleased to announce that Mr Gene Williams has been appointed as a
non-executive director with effect from 19 th January 2001. Dr Peder Jensen, non-executive
director, will retire from the Board on 31 st January 2001.
Mr Williams, aged 41, is currently Vice President, Therapeutics Program Management at
Genzyme Corporation, Cambridge, MA where he is responsible for the department
which oversees development stage projects, including portfolio management and
integrating market and business assessments into the drug discovery and development
process. Mr Williams has 18 years experience in healthcare. He serves on the Board of
Directors of Adheris, Inc., and is on the Drug Information Associations Marketing
Advisory Board. He qualified BA, Magna Cum Laude, Economics from Harvard College
in 1982 and MBA, Harvard Business School in 1987.
Chris Hampson, Chairman, British Biotech, commented: "On behalf of the Board, I
would like to thank Peder Jensen for his contribution to the Company over the last three
years, first as an executive director and, more recently, in a non-executive role. I am
delighted to welcome Gene to the Board. His broad experience of strategic marketing
and business development within healthcare complements our existing strengths in this
area."
Ends
For further information, please contact:
British Biotech plc
Tony Weir, Finance Director Tel: [phone]
Fax: [phone]
www.britishbiotech.com
Financial Dynamics
Sarah Mehanna/David Yates Tel: [phone]
Fax: [phone]
www.fd.com

Embargoed until 7am 19 th January 2001
British Biotech plc ("British Biotech")
British Biotech announces update on marimastat Studies 140
and 117 in patients with small cell lung cancer
Study 140, a clinical trial of the oral matrix metalloproteinase inhibitor, marimastat, in
patients with small cell lung cancer has been completed and the data have been collected.
The analysis of the data by British Biotech is being initiated and, when complete, the
results will be reviewed with our collaborators, Schering-Plough Corporation and Tanabe
Seiyaku Co. Ltd. It is anticipated the results will be announced by the end of February.
A second trial of marimastat in small cell lung cancer (Study 117/NCIC CTG
BR.12/EORTC 08962) has also been completed and the analysis of the data by the NCIC
CTG and EORTC is being initiated. British Biotech, the NCIC CTG and EORTC will be
sharing results of the completed analyses of Study 140 and Study 117. The NCIC CTG
and EORTC are planning to present the results of Study 117 at the American Society of
Clinical Oncology meeting in San Francisco in May 2001.
Worldwide rights to develop MMPIs in cancer are owned by Schering-Plough, excluding
Japan and certain Far Eastern territories, where Tanabe Seiyaku has development rights.
Dr Elliot Goldstein, Chief Executive Officer, stated : "Given the importance of these two
studies for the marimastat programme we thought it useful to define the timetable and
clarify when the results of the small cell lung cancer studies will be communicated".
Definitions:
NCIC CTG : National Cancer Institute of Canada Clinical Trials Group
EORTC : European Organisation for the Research and Treatment of Cancer
Ends

For immediate release 19 th January 2001
British Biotech plc ("British Biotech")
Clarification to marimastat announcement of 19 th January 2001
The analysis by the NCIC CTG and EORTC of its small cell lung cancer study (Study
117) will be completed and shared with British Biotech by the end of February. British
Biotech will therefore be in a position, by the end of February, to announce the results of
its own small cell lung cancer study (Study 140) and whether or not the outcome of
Study 117 is consistent with the results of Study 140.
Definitions:
NCIC CTG : National Cancer Institute of Canada Clinical Trials Group
EORTC : European Organisation for the Research and Treatment of Cancer
Ends
For further information, please contact:
British Biotech plc
Tony Weir, Finance Director Tel: [phone]
Fax: [phone]
www.britishbiotech.com
Financial Dynamics
Sarah Mehanna/David Yates Tel: [phone]
Fax: [phone]
www.fd.com
This news release contains forward-looking statements, which reflect the Company`s current expectation
regarding future events. Forward-looking statements involve risks and uncertainties. Actual events
could differ materially from those projected herein and depend on a number of factors including the
success of the Company`s research strategy, the applicability of the discoveries made therein, the
successful and timely completion of clinical studies and the uncertainties related to the regulatory
process.


Bis Bald User5